Kosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment
HAYWARD, CaliforniaKosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment. Approximately 470 patients with first-relapse disease will be randomized to treatment with bortezomib (Velcade) plus tanespimycin or bortezomib alone.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.